AGM/EGMAug 3, 2026, 05:13 PM
Cadrenal Sets AGM, Seeks Approval for Equity Plan & Warrants
AI Summary
Cadrenal Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 24, 2026. Stockholders will vote on several key proposals, including the election of a Class I director, the ratification of its independent auditor, and significant equity-related matters. These include an amendment to increase the 2022 Equity Incentive Plan shares by 323,542 to a total of 1,000,000, and the approval for the issuance of up to 960,000 shares upon the exercise of Series C-1 warrants from a recent private placement.
Key Highlights
- Annual Meeting of Stockholders to be held virtually on September 24, 2026.
- Record date for voting is July 27, 2026.
- Proposing to increase 2022 Equity Incentive Plan shares by 323,542 to 1,000,000.
- Seeking approval for issuance of up to 960,000 shares from Series C-1 warrant exercise.
- Stockholders to vote on the election of Class I director, Quang X. Pham.
- Ratification of WithumSmith+Brown, PC as independent auditor for fiscal year 2026.
Price Impact
More from CVKD